Ultime notizie per Braze (NASDAQ:BRZE) Azioni

BRAZE INC-A

Braze

Braze Inc is a customer engagement platform that powers customer-centric interactions between consumers and brands. The company provides solutions for Retail & E-commerce, Media & Entertainment, Financial Services, and Travel & Hospitality related industries. The company offers a single, vertically integrated platform that encompasses the various functionalities, or layers, required for modern customer engagement: data ingestion, classification, orchestration, personalization, and action, all of which is supported by Sage AI by Braze, its AI engine designed to power AI functionality across all layers of this stack. It generates majority of its revenue from the United States.

Lululemon Athletica Inc. LULU

Equities

News

Pre-Market Outlook

Markets

Trading Ideas

BRZE

KPLT

LULU

Risultati trimestrali e reazioni del mercato. Lululemon, Braze e Super League: cosa si muove e perché. Analisi e prospettive.

Wall Street in diretta: i titoli da tenere d&#39;occhio oggi. Le ultime novità

Braze Inc

HC Wainwright &amp; Co. analyst Ed Arce reiterates Unicycive Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UNCY#NASDAQ">UNCY</a>) with a Buy and maintains $7.5 price target.

Price Target

Reiteration

Analyst Ratings

UNCY

HC Wainwright & Co. Reiterates Buy on Unicycive Therapeutics, Maintains $7.5 Price Target

Earnings

JPMorgan Chase CEO Jamie Dimon: "The economy is facing considerable turbulence (including geopolitics), with the potential positives of tax reform and deregulation and the potential negatives of tariffs and "trade wars," ongoing sticky inflation, high fiscal deficits and still rather high asset prices and volatility."

Fastenal (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FAST#NASDAQ">FAST</a>) reported quarterly earnings of $0.52 per share which met the analyst consensus estimate. This is unchanged from the same period last year. The company reported quarterly sales of $1.96 billion which beat the analyst consensus estimate of $1.95 billion by 0.45 percent. This is a 3.38 percent increase over sales of $1.90 billion the same period last year.

Earnings Beats

FAST

Fastenal Q1 2025 GAAP EPS $0.52, Inline, Sales $1.96B Beat $1.95B Estimate

Keefe, Bruyette &amp; Woods analyst Brady Gailey maintains Bank7 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BSVN#NASDAQ">BSVN</a>) with a Outperform and lowers the price target from $50 to $47.

BSVN

Keefe, Bruyette & Woods Maintains Outperform on Bank7, Lowers Price Target to $47

HC Wainwright &amp; Co. analyst Vernon Bernardino reiterates Candel Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CADL#NASDAQ">CADL</a>) with a Buy and maintains $19 price target.

CADL

HC Wainwright & Co. Reiterates Buy on Candel Therapeutics, Maintains $19 Price Target

JPMorgan Chase (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JPM#NYSE">JPM</a>) reported quarterly earnings of $5.07 per share which beat the analyst consensus estimate of $4.62 by 9.74 percent. This is a 14.19 percent increase over earnings of $4.44 per share from the same period last year. The company reported quarterly sales of $46.014 billion which beat the analyst consensus estimate of $44.111 billion by 4.31 percent. This is a 8.15 percent increase over sales of $42.548 billion the same period last year.

JPMorgan Chase Q1 2025 GAAP EPS $5.07 Beats $4.62 Estimate, Sales $46.014B Beat $44.111B Estimate

Wells Fargo Q1 net Interest Income Decreased 6%, Driven By The Impact Of Lower Interest Rates On Floating Rate Assets, Deposit Mix And Pricing Changes, Lower Loan Balances, And One Fewer Day In The Quarter, Partially Offset By Lower Market Funding

Needham analyst Mike Matson reiterates Lucid Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUCD#NASDAQ">LUCD</a>) with a Buy and maintains $3 price target.

LUCD

Needham Reiterates Buy on Lucid Diagnostics, Maintains $3 Price Target

Goldman Sachs analyst Noah Poponak downgrades Booz Allen Hamilton (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAH#NYSE">BAH</a>) from Buy to Neutral and lowers the price target from $150 to $109.

Downgrades

Goldman Sachs Downgrades Booz Allen Hamilton to Neutral, Lowers Price Target to $109

HC Wainwright &amp; Co. analyst Yi Chen reiterates VolitionRX (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/VNRX#AMEX">VNRX</a>) with a Buy and maintains $2.5 price target.

VNRX

HC Wainwright & Co. Reiterates Buy on VolitionRX, Maintains $2.5 Price Target

Earnings Misses

Wells Fargo Q1 2025 GAAP EPS $1.39 Beats $1.22 Estimate, Sales $20.149B Miss $20.748B Estimate

Goldman Sachs analyst Noah Poponak downgrades Planet Labs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PL#NYSE">PL</a>) from Buy to Neutral and lowers the price target from $6 to $3.5.

Goldman Sachs Downgrades Planet Labs to Neutral, Lowers Price Target to $3.5

Needham analyst Serge Belanger reiterates Heron Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HRTX#NASDAQ">HRTX</a>) with a Buy and maintains $4 price target.

HRTX

Needham Reiterates Buy on Heron Therapeutics, Maintains $4 Price Target

HC Wainwright &amp; Co. analyst Douglas Tsao reiterates argenx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARGX#NASDAQ">ARGX</a>) with a Buy and maintains $720 price target.

ARGX

HC Wainwright & Co. Reiterates Buy on argenx, Maintains $720 Price Target

Goldman Sachs analyst Gavin Parsons upgrades Booz Allen Hamilton (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAH#NYSE">BAH</a>) from Buy to Neutral and lowers the price target from $150 to $109.

Upgrades

Goldman Sachs Upgrades Booz Allen Hamilton to Neutral, Lowers Price Target to $109

As of April 11, 2025, two stocks in the consumer discretionary sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the<a href="https://www.benzinga.com/topic/rsi"> RSI is above 70</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>. 
Here's the latest list of major overbought players in this sector.
<h3 class="wp-block-heading">Raytech Holding Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RAY#NASDAQ">RAY</a>)</h3>
<ul>
<li>On Jan. 10, Raytech posted a 6-month EPS of 3 cents and revenue of $5.56 million. CHING Tim Hoi, CEO and Chairman of the Company, commented, &#8220;The Company achieved a notable 31.0% increase in revenue for the six months ended September 30, 2024, reaching HKD 43.2 million (US$ 5.6 million), up from HKD 33.0 million in the prior year. This growth was driven primarily by strong sales in our trimmer series within the personal care products segment, reflecting our success in attracting new customers.&#8221; The company's stock jumped around 39% over the past month and has a 52-week high of $6.04.</li>
<li>RSI Value: 72.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li>RAY Price Action: Shares of Raytech gained 6.3% to close at $2.35 on Thursday.</li>
<li>Edge Stock Ratings: Value at 61.96. </li>
</ul>
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/quote/ray"><img loading="lazy" decoding="async" width="510" height="185" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/11055609/image-76.png" alt="" class="wp-image-867571" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/11055609/image-76.png 510w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/11055609/image-76-300x109.png 300w" sizes="(max-width: 510px) 100vw, 510px" /></a></figure>
<h3 class="wp-block-heading">ThredUp Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TDUP#NASDAQ">TDUP</a>)</h3>
<ul>
<li>ThredUp will release its financial results for the first quarter ended March 31 on Monday, May 5, after the close of the U.S. markets. The company's stock gained around 38% over the past five days and <a href="https://www.benzinga.com/quote/TDUP">has a 52-week high</a> of $3.40.</li>
<li>RSI Value: 74.8</li>
<li>TDUP Price Action: Shares of ThredUp gained 4.8% to close at $3.30 on Thursday. </li>
</ul>
Don't miss out on the full BZ Edge Rankings—<a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">compare all the key stocks now</a>. 
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/04/44734419/top-2-real-estate-stocks-that-may-keep-you-up-at-night-this-month">Top 2 Real Estate Stocks That May Keep You Up At Night This Month</a> </li>
</ul>
Photo via Shutterstock

Short Ideas

TDUP

Top 2 Consumer Stocks That May Collapse This Quarter

Keybanc analyst Bradley Thomas initiates coverage on Murphy USA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MUSA#NYSE">MUSA</a>) with a Overweight rating and announces Price Target of $550.

Initiation

MUSA

Keybanc Initiates Coverage On Murphy USA with Overweight Rating, Announces Price Target of $550

Goldman Sachs analyst Noah Poponak upgrades Northrop Grumman (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOC#NYSE">NOC</a>) from Sell to Neutral and raises the price target from $424 to $521.

Goldman Sachs Upgrades Northrop Grumman to Neutral, Raises Price Target to $521

Keybanc analyst Bradley Thomas initiates coverage on Casey's General Stores (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CASY#NASDAQ">CASY</a>) with a Overweight rating and announces Price Target of $500.

CASY

Keybanc Initiates Coverage On Casey's General Stores with Overweight Rating, Announces Price Target of $500

Goldman Sachs analyst Noah Poponak upgrades L3Harris Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LHX#NYSE">LHX</a>) from Sell to Buy and raises the price target from $198 to $263.

Comments

Braze

Notizie

Ultime notizie per Braze (NASDAQ:BRZE) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO